Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 479-484

  Coffin, Carla S ^a   Fraser, Hughie F ^a   Panaccione, Remo ^a   Ghosh, Subrata ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

anti TNF alpha; hepatotoxicity; inflammatory bowel disease; liver disease

Indexed keywords

ADALIMUMAB; ADEFOVIR; AZATHIOPRINE; CERTOLIZUMAB PEGOL; ENTECAVIR; ETANERCEPT; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INFLIXIMAB; ISONIAZID; LAMIVUDINE; MEPREDNISONE; METHOTREXATE; PLACEBO; PREDNISONE; RIFAMPICIN; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY;

CANCER GROWTH; CHOLESTASIS; CHRONIC LIVER DISEASE; COLON CROHN DISEASE; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG INDUCED HEPATOTOXICITY; DRUG SUBSTITUTION; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; HYPERTRANSAMINASEMIA; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER TOXICITY; NEPHROTOXICITY; NODULAR HYPERPLASIA; NODULAR REGENERATIVE HYPERPLASIA; NONALCOHOLIC FATTY LIVER; NONHUMAN; OPPORTUNISTIC INFECTION; PELIOSIS HEPATITIS; PORTAL HYPERTENSION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; T CELL LYMPHOMA; TOXIC HEPATITIS; TUBERCULOSIS; ULCERATIVE COLITIS; VEIN OCCLUSION; VIRUS LOAD; VIRUS REACTIVATION;

HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650140223     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21336     Document Type: Review

References (76)

1. Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010: 31: 20-34.
2. Mindikoglu AL, Regev A, Schiff ER,. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol. 2006; 4: 1076-1081.
3. Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996; 4: 25-36.
4. del Valle GSM, Gõmez-Camacho F, Poyato-González A, et al. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis. 2004; 10: 701-722.
5. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003; 62: 686-687.
6. Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004; 53: 1363-1365.
7. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006; 12: 974-976.
8. Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci. 2005; 50: 163-166.
9. Wendling D, Auge B, Bettinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis. 2005; 64: 788-789.
10. Anelli MG, Torres DD, Manno C, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum. 2005; 52: 2519-2520.
11. Sakellariou GT, Chatzigiannis I,. Long-term anti-TNF alpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol. 2007; 26: 950-952.
12. Madonia S, Orlando A, Scimeca D, et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007; 13: 508-509.
13. Colbert C, Chavarria A, Berkelhammer C,. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis. 2007; 13: 1453-1454.
14. Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int. 2008; 28: 718-720.
15. Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol. 2008; 43: 397-401.
16. Benucci M, Manfredi M, Mecocci L,. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol. 2008; 14: 245-246.
17. Robinson H, Walker-Bone K,. Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford). 2009; 48: 448-450.
18. Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol. 2003; 30: 1624-1625.
19. Li S, Kaur PP, Chan V, et al. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab,etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol. 2009; 28: 787-791.
20. Cansu DU, Kalifoglu T, Korkmaz C,. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol. 2008; 35: 421-424.
21. Kaur PP, Chan VC, Berney SN,. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol. 2008; 27: 1069-1071.
22. Calabrese LH, Zein N, Vassilopoulos D,. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis. 2004; 63 (suppl 2): ii18-ii24.
23. Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol. 2004; 31: 107-109.
24. Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford). 2006; 45: 1294-1297.
25. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008; 49: 652-657.
26. Raimondo G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection. J Hepatol. 2007; 46: 160-170.
27. Campbell S, Ghosh S,. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol. 2001; 13: 191-192.
28. Parke FA, Reveille JD,. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum. 2004; 51: 800-804.
29. Holtmann MH, Galle PR, Neurath MF,. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol. 2003; 98: 504-505.
30. Magliocco MA, Gottlieb AB,. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol. 2004; 51: 580-584.
31. Aslanidis S, Vassiliadis T, Pyrpasopoulou A, et al. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: 2 cases. Clin Rheumatol. 2007; 26: 261-264.
32. Marotte H, Fontanges E, Bailly F, et al. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford). 2007; 46: 97-99.
33. Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003; 62: 1078-1082.
34. Niewold TB, Gibofsky A,. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum. 2006; 54: 2335-2337.
35. Rokhsar C, Rabhan N, Cohen SR,. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol. 2006; 54: 361-362.
36. De Simone C, Paradisi A, Capizzi R, et al. Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol. 2006; 54: 1102-1104.
37. Cassano N, Vena GA,. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. Int J Dermatol. 2008; 47: 980-981.
38. Cecchi R, Bartoli L,. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept). Dermatol Online J. 2006; 12: 4.
39. Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol. 2008; 35: 1944-1949.
40. Linardaki G, Katsarou O, Ioannidou P, et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol. 2007; 34: 1353-1355.
41. Cavazzana I, Ceribelli A, Cattaneo R, et al. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev. 2008; 8: 104-106.
42. Abdelmalek MF, Liu C, Valentine JF,. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am J Gastroenterol. 2007; 102: 1333-1334. (Pubitemid 46802003)
43. Bellisai F, Giannitti C, Donvito A, et al. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol. 2007; 26: 1127-1129.
44. Zein NN,; Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005; 42: 315-322.
45. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology. 1999; 30: 1356-1362.
46. Marrero Ja, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with heptaocellular carcinoma in the United States. Hepatology. 2002; 36: 1349-1354.
47. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003; 36: 417-420.
48. Gisbert JP, Luna M, González-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007; 13: 1106-1114.
49. Koca SS, Bahcecioglu IH, Poyrazoglu OK, et al. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation. 2008; 31: 91-98.
50. Scharmm C, Schneider A, Marx A, et al. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol. 2008; 46: 1369-1371.
51. Rasmussen HH, Fallingborg JF, Mortensen PB, et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol. 1997; 32: 604-610.
52. Bo X, Broome U, Remberger M, et al. Tumour necrosis factor alpha impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut. 2001; 49: 131-141.
53. Barrie A, Regueiro M,. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2007: 13: 1424-1429. (Pubitemid 350206857)
54. United States Food and Drug Administration. 2009 Remicade Label and Approval History. Accessed November 2, 2009.
55. Ramos-Casals M, Brito-Zerõn P, Soto MJ, et al. Autoimmune disease induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008; 22: 847-861.
56. Carlsen KM, Riis L, Madsen OR,. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol. 2009; 28: 1001-1003.
57. Lee WM,. Drug-induced hepatotoxicity. N Engl J Med. 2003; 349: 474-485.
58. Theis VS, Rhodes JM,. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 27: 19-30.
59. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004; 50: 372-379. (Pubitemid 38198820)
60. Columbel JF, Lofuts ET, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004; 126: 19-31.
61. Lichtenstein GR,. Revisiting safety considerations of biologic therapy. 2004. Accessed November 1, 2009.
62. Page KR, Sifakis R, Montes de Oca R, et al. Improved adherence and less toxicity with rifampicin vs isoniazid for treatment for latent TB: a retrospective study. Arch Intern Med. 2006; 166: 1863-1870.
63. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent TB infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005; 52: 1766-1772.
64. Sichletidis L, Settas L, Spyratos D, et al. TB in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006; 10: 1127-1132.
65. Mitchell JR, Long MW, Thoreirsson UP, et al. Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy. Chest. 1975; 68: 181-190.
66. Zabana Y, Domenech E, San Roman AL, et al. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis. 2008; 14: 1387-1391.
67. Cagatay T, Aydin M, Sunmez S, et al. Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int. 2009 [Epub ahead of print].
68. American Thoracic Society. Targeted tuberculin testing and treatment of latent TB infection. Am J Respir Crit Care Med. 2000; 161: S221-247.
69. CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR. 2000; 49 (No.RR-10).
70. Wong GH, Goeddel DV,. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature. 1986; 323: 819-822.
71. Lavagna A, Bergallo M, Daperno M, et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis. 2007; 13: 896-902.
72. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007; 44: 265-267.
73. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with anti-TNF agents for the treatment of Crohn's disease: a meta-analysis. Gastroenterology. 2008; 134 (suppl 1): A144.
74. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry. Clin Gastroenterol Hepatol. 2006; 4: 621-630.
75. Bonnet F, Neau D, Viallard JF, et al. Clinical and laboratory findings of cytomegalovirus infection in 15 hospitalized nonimmunocompromised adults. Ann Med Interne. (Paris) 2001; 152: 227-235.
76. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut. 2007; 56: 1404-1409. (Pubitemid 47517834)